- Home
- PANW vs GSK Comparison
PANW vs GSK Comparison
Compare PANW & GSK Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | PANW | GSK |
|---|---|---|
| Founded | 2005 | 1715 |
| Country | United States | United Kingdom |
| Employees | N/A | N/A |
| Industry | Computer peripheral equipment | Biotechnology: Pharmaceutical Preparations |
| Sector | Technology | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 126.9B | 102.0B |
| IPO Year | 2012 | N/A |
Fundamental Metrics
Financial Performance| Metric | PANW | GSK |
|---|---|---|
| Price | $191.22 | $50.23 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 40 | 2 |
| Target Price | ★ $227.35 | N/A |
| AVG Volume (30 Days) | ★ 5.6M | 3.3M |
| Earning Date | 02-12-2026 | 02-04-2026 |
| Dividend Yield | N/A | ★ 3.28% |
| EPS Growth | N/A | ★ 118.57 |
| EPS | 1.58 | ★ 1.79 |
| Revenue | $9,556,500,000.00 | ★ $43,237,357,842.00 |
| Revenue This Year | $16.46 | $6.70 |
| Revenue Next Year | $13.25 | $5.10 |
| P/E Ratio | $122.72 | ★ $28.34 |
| Revenue Growth | ★ 15.30 | 2.73 |
| 52 Week Low | $144.15 | $31.72 |
| 52 Week High | $223.61 | $51.46 |
Technical Indicators
Market Signals| Indicator | PANW | GSK |
|---|---|---|
| Relative Strength Index (RSI) | 52.34 | 63.52 |
| Support Level | $177.23 | $48.59 |
| Resistance Level | $196.19 | $51.46 |
| Average True Range (ATR) | 3.92 | 0.59 |
| MACD | 1.09 | 0.08 |
| Stochastic Oscillator | 75.21 | 64.56 |
Price Performance
Historical ComparisonAbout PANW Palo Alto Networks Inc.
Palo Alto Networks is a platform-based cybersecurity vendor with product offerings covering network security, cloud security, and security operations. The California-based firm has more than 80,000 enterprise customers across the world, including more than three fourths of the Global 2000.
About GSK GSK plc (Each representing two)
In the pharmaceutical industry, GSK ranks as one of the largest firms by total sales. The company wields its might across several therapeutic classes, including respiratory, antiviral, and vaccines, and has been growing its presence in oncology and immunology, as well. GSK uses joint ventures to gain additional scale in certain markets like HIV.